Nuplazid NDA delayed, again; Acadia CEO steps down
This article was originally published in Scrip
Executive Summary
Shares of Acadia Pharmaceuticals plummeted 30% in after-hours trading on 11 March after the firm revealed it was again delaying its new drug application (NDA) submission for its investigational Parkinson's disease psychosis drug Nuplazid (pimavanserin) – this time pushing it out until the second half of the year.